[1]
|
Stark, J. (1999) PRESERVATIVES|Permitted Preservatives—Natamycin. Encyclopedia of Food Microbiology, 1776-1781. https://doi.org/10.1006/rwfm.1999.2080
|
[2]
|
Thomas, A.H. (1976) Analysis and Assay of Polyene Antifungal Antibiotics. A Review. Analyst, 101, 321-340.
https://doi.org/10.1039/an9760100321
|
[3]
|
Wang, D., Shen, W., Yuan, J., et al. (2021) Advances in the Biosyn-thesis of Natamycin and Its Regulatory Mechanisms. Chinese Journal of Bioengineering, 37, 1107-1119.
|
[4]
|
Dekker, J. and Ark, P.A. (1959) Protection of Antibiotic Pimaricin from Oxidation and Ultraviolet Light by Chlorophyllin and Other Compounds. Antibiot Chemother (Northfield), 9, 327-332.
|
[5]
|
Brik, H. (1976) New High-Molecular Decomposition Products of Natamycin (Pimaricin) with Intact Lactone-Ring. The Journal of Antibiotics (Tokyo), 29, 632-637. https://doi.org/10.7164/antibiotics.29.632
|
[6]
|
Brothers, A.M. and Wyatt, R.D. (2000) The Antifungal Activity of Natamycin toward Molds Isolated from Commercially Manufactured Poultry Feed. Avian Diseases, 44, 490-497. https://doi.org/10.2307/1593087
|
[7]
|
Al-Hatmi, A.M., Meletiadis, J., Curfs-Breuker, I., et al. (2016) In Vitro Combinations of Natamycin with Voriconazole, Itraconazole and Micafungin against Clinical Fusarium Strains Causing Keratitis. Journal of Antimicrobial Chemotherapy, 71, 953-955. https://doi.org/10.1093/jac/dkv421
|
[8]
|
Van Leeuwen, M.R., Golovina, E.A. and Dijksterhuis, J. (2009) The Polyene Antimycotics Nystatin and Filipin Disrupt the Plasma Membrane, Whereas Natamycin Inhibits Endocytosis in Germinating Conidia of Penicillium Discolor. Journal of Applied Microbiology, 106, 1908-1918. https://doi.org/10.1111/j.1365-2672.2009.04165.x
|
[9]
|
Te Welscher, Y.M., Ten Napel, H.H., Balagué, M.M., et al. (2008) Natamycin Blocks Fungal Growth by Binding Specifically to Ergosterol without Permeabilizing the Membrane. Journal of Biological Chemistry, 283, 6393-6401.
https://doi.org/10.1074/jbc.M707821200
|
[10]
|
Takeda, T. and Chang, F. (2005) Role of Fission Yeast Myosin I in Organization of Sterol-Rich Membrane Domains. Current Biology, 15, 1331-1336. https://doi.org/10.1016/j.cub.2005.07.009
|
[11]
|
Kato, M. and Wickner, W. (2001) Ergosterol Is Required for the Sec18/ATP-Dependent Priming Step of Homotypic Vacuole Fusion. The EMBO Journal, 20, 4035-4040. https://doi.org/10.1093/emboj/20.15.4035
|
[12]
|
Munn, A.L. (2001) Molecular Requirements for the Internalisation Step of Endocytosis: Insights from Yeast. Biochimica et Biophysica Acta, 1535, 236-257. https://doi.org/10.1016/S0925-4439(01)00028-X
|
[13]
|
Te Welscher, Y.M., Jones, L., Van Leeuwen, M.R., et al. (2010) Natamycin Inhibits Vacuole Fusion at the Priming Phase via a Specific Interaction with Ergosterol. Antimicrobial Agents and Chemotherapy, 54, 2618-2625.
https://doi.org/10.1128/AAC.01794-09
|
[14]
|
Baars, T.L., Petri, S., Peters, C., et al. (2007) Role of the V-ATPase in Regulation of the Vacuolar Fission-Fusion Equilibrium. Molecular Biology of the Cell, 18, 3873-3882. https://doi.org/10.1091/mbc.e07-03-0205
|
[15]
|
Wickner, W. and Haas, A. (2000) Yeast Homotypic Vacuole Fusion: A Window on Organelle Trafficking Mechanisms. Annual Review of Biochemistry, 69, 247-275. https://doi.org/10.1146/annurev.biochem.69.1.247
|
[16]
|
Heese-Peck, A., Pichler, H., Zanolari, B., et al. (2002) Multiple Functions of Sterols in Yeast Endocytosis. Molecular Biology of the Cell, 13, 2664-2680. https://doi.org/10.1091/mbc.e02-04-0186
|
[17]
|
Mayer, A. (2002) Membrane Fusion in Eukaryotic Cells. Annual Review of Cell and Developmental Biology, 18, 289-314. https://doi.org/10.1146/annurev.cellbio.18.032202.114809
|
[18]
|
Munn, A.L., Heese-Peck, A., Stevenson, B.J., et al. (1999) Specific Sterols Required for the Internalization Step of Endocytosis in Yeast. Molecular Biology of the Cell, 10, 3943-3957. https://doi.org/10.1091/mbc.10.11.3943
|
[19]
|
Ozcan, S. and Johnston, M. (1999) Function and Regula-tion of Yeast Hexose Transporters. Microbiology and Molecular Biology Reviews, 63, 554-569. https://doi.org/10.1128/MMBR.63.3.554-569.1999
|
[20]
|
Regenberg, B., Düring-Olsen, L., Kielland-Brandt, M.C., et al. (1999) Substrate Specificity and Gene Expression of the Amino-Acid Permeases in Saccharomyces cerevisiae. Current Genetics, 36, 317-328.
https://doi.org/10.1007/s002940050506
|
[21]
|
Te Welscher, Y.M., Van Leeuwen, M.R., De Kruijff, B., et al. (2012) Polyene Antibiotic That Inhibits Membrane Transport Proteins. Proceedings of the National Academy of Sciences of the United States of America, 109, 11156-11159.
https://doi.org/10.1073/pnas.1203375109
|
[22]
|
Bourcier, T., Sauer, A., Dory, A., et al. (2017) Fungal Keratitis. Journal Français d’Ophtalmologie, 40, 882-888.
https://doi.org/10.1016/j.jfo.2017.05.013
|
[23]
|
Collier, S.A., Gronostaj, M.P., Macgurn, A.K., et al. (2014) Esti-mated Burden of Keratitis—United States, 2010. The Morbidity and Mortality Weekly Report, 63, 1027-1030.
|
[24]
|
Manikandan, P., Abdel-Hadi, A., Randhir Babu Singh, Y., et al. (2019) Fungal Keratitis: Epidemiology, Rapid Detection, and Antifungal Susceptibilities of Fusarium and Aspergillus Isolates from Corneal Scrapings. BioMed Research International, 2019, Article ID: 6395840. https://doi.org/10.1155/2019/6395840
|
[25]
|
Lalitha, P., Vijaykumar, R., Prajna, N.V., et al. (2008) In Vitro Natamycin Susceptibility of Ocular Isolates of Fusarium and Asper-gillus Species: Comparison of Commercially Formulated Natamycin Eye Drops to Pharmaceutical-Grade Powder. Jour-nal of Clinical Microbiology, 46, 3477-3478. https://doi.org/10.1128/JCM.00610-08
|
[26]
|
Lalitha, P., Shapiro, B.L., Srinivasan, M., et al. (2007) Antimicrobial Susceptibility of Fusarium, Aspergillus, and Other Filamentous Fungi Isolat-ed from Keratitis. Archives of Ophthalmology, 125, 789-793.
https://doi.org/10.1001/archopht.125.6.789
|
[27]
|
Prajna, N.V., Lalitha, P., Krishnan, T., et al. (2022) Patterns of Antifungal Resistance in Adult Patients with Fungal Keratitis in South India: A Post Hoc Analysis of 3 Randomized Clinical Trials. JAMA Ophthalmology, 140, 179-184.
https://doi.org/10.1001/jamaophthalmol.2021.5765
|
[28]
|
Mahmoudi, S., Masoomi, A., Ahmadikia, K., et al. (2018) Fungal Keratitis: An Overview of Clinical and Laboratory Aspects. Mycoses, 61, 916-930. https://doi.org/10.1080/21691401.2018.1443117
|
[29]
|
Janga, K.Y., Tatke, A., Balguri, S.P., et al. (2018) Ion-Sensitive in Situ Hydrogels of Natamycin Bilosomes for Enhanced and Prolonged Ocular Pharmacotherapy: In Vitro Permeability, Cytotoxicity and in Vivo Evaluation. Artificial Cells, Nanomedicine, and Biotechnology, 46, 1039-1050. https://doi.org/10.1080/21691401.2018.1443117
|
[30]
|
Amit, C., Muralikumar, S., Janaki, S., et al. (2019) Design-ing and Enhancing the Antifungal Activity of Corneal Specific Cell Penetrating Peptide Using Gelatin Hydrogel Delivery System. International Journal of Nanomedicine, 14, 605-622. https://doi.org/10.2147/IJN.S184911
|
[31]
|
Khames, A., Khaleel, M.A., El-Badawy, M.F., et al. (2019) Natamycin Solid Lipid Nanoparticles-Sustained Ocular Delivery Sys-tem of Higher Corneal Penetration against Deep Fungal Keratitis: Preparation and Optimization. International Journal of Nanomedicine, 14, 2515-2531. https://doi.org/10.2147/IJN.S190502
|
[32]
|
Rohira, H., Shankar, S., Yadav, S., et al. (2021) Enhanced in Vivo Antifungal Activity of Novel Cell Penetrating Peptide Natamycin Conjugate for Efficient Fungal Keratitis Management. International Journal of Pharmaceutics, 600, Article ID: 120484. https://doi.org/10.1016/j.ijpharm.2021.120484
|
[33]
|
El-Nabarawi, M.A., Abd El Rehem, R.T., Teaima, M., et al. (2019) Natamycin Niosomes as a Promising Ocular Nanosized Delivery System with Ketorolac Tromethamine for Dual Effects for Treatment of Candida Rabbit Keratitis; in Vitro/in Vivo and Histopathological Studies. Drug Development and Industrial Pharmacy, 45, 922-936.
https://doi.org/10.1080/03639045.2019.1579827
|
[34]
|
Guo, Y., Karimi, F., Fu, Q., et al. (2020) Reduced Admin-istration Frequency for the Treatment of Fungal Keratitis: A Sustained Natamycin Release from a Micellar Solution. Ex-pert Opinion on Drug Delivery, 17, 407-421.
https://doi.org/10.1080/17425247.2020.1719995
|
[35]
|
Lorenzo-Veiga, B., Sigurdsson, H.H., Loftsson, T., et al. (2019) Cyclodextrin-Amphiphilic Copolymer Supramolecular Assemblies for the Ocular Delivery of Natamycin. Nano-materials, 9, 745. https://doi.org/10.3390/nano9050745
|
[36]
|
忻丹丽, 沈降, 潘飞. 那他霉素联合伊曲康唑治疗真菌性角膜炎的疗效分析[J]. 中国现代医学杂志, 2017, 27(20): 73-75.
|
[37]
|
郑振扬, 叶忠强. 那他霉素联合伏立康唑治疗真菌性角膜炎的疗效分析[J]. 中国实用医药, 2020, 15(30): 155-157.
|
[38]
|
霍灿明, 萧少雄, 袁启贤, 等. 维生素A和环孢素A治疗干眼症的临床对比分析[J]. 心电图杂志(电子版), 2019, 8(4): 118-119.
|
[39]
|
梁静. 环孢素联合那他霉素治疗真菌性角膜炎的效果观察[J]. 河南医学高等专科学校学报, 2020, 32(5): 513-515.
|
[40]
|
Ansari, Z., Miller, D. and Galor, A. (2013) Current Thoughts in Fungal Keratitis: Diagnosis and Treat-ment. Current Fungal Infection Reports, 7, 209-218. https://doi.org/10.1007/s12281-013-0150-1
|
[41]
|
Rao, S.K., Madhavan, H.N., Rao, G., et al. (1997) Fluconazole in Filamentous Fungal Keratitis. Cornea, 16, 700.
https://doi.org/10.1097/00003226-199711000-00019
|
[42]
|
Prajna, N.V., Mascarenhas, J., Krishnan, T., et al. (2010) Comparison of Natamycin and Voriconazole for the Treatment of Fungal Keratitis. Archives of Ophthalmology, 128, 672-678. https://doi.org/10.1001/archophthalmol.2010.102
|
[43]
|
Patil, A. and Majumdar, S. (2017) Echinocandins in Ocular Therapeutics. Journal of Ocular Pharmacology and Therapeutics, 33, 340-352. https://doi.org/10.1089/jop.2016.0186
|
[44]
|
Kaur, I.P. and Kakkar, S. (2010) Topical Delivery of Antifungal Agents. Expert Opinion on Drug Delivery, 7, 1303-1327. https://doi.org/10.1517/17425247.2010.525230
|
[45]
|
Thomas, P.A. (2003) Fungal Infections of the Cornea. Eye, 17, 852-862.
https://doi.org/10.1038/sj.eye.6700557
|
[46]
|
Chandasana, H., Prasad, Y.D., Chhonker, Y.S., et al. (2014) Corneal Targeted Nanoparticles for Sustained Natamycin Delivery and Their PK/PD Indices: An Approach to Reduce Dose and Dosing Frequency. International Journal of Pharmaceutics, 477, 317-325. https://doi.org/10.1016/j.ijpharm.2014.10.035
|
[47]
|
Bhatta, R.S., Chandasana, H., Chhonker, Y.S., et al. (2012) Mucoadhesive Nanoparticles for Prolonged Ocular Delivery of Natamycin: In Vitro and Pharmacokinetics Studies. In-ternational Journal of Pharmaceutics, 432, 105-112.
https://doi.org/10.1016/j.ijpharm.2012.04.060
|
[48]
|
Koontz, J.L. and Marcy, J.E. (2003) Formation of Natamycin: Cyclodextrin Inclusion Complexes and Their Characterization. Journal of Agricultural and Food Chemistry, 51, 7106-7110. https://doi.org/10.1021/jf030332y
|
[49]
|
Badhani, A., Dabral, P., Rana, V., et al. (2012) Evaluation of Cyclodextrins for Enhancing Corneal Penetration of Natamycin Eye Drops. Journal of Pharmacy & Bioallied Sciences, 4, S29-S30. https://doi.org/10.4103/0975-7406.94128
|
[50]
|
Tu, J., Pang, H., Yan, Z., et al. (2007) Ocular Permeabil-ity of Pirenzepine Hydrochloride Enhanced by Methoxy Poly(ethylene glycol)-Poly(D,L-lactide) Block Copolymer. Drug Development and Industrial Pharmacy, 33, 1142-1150.
https://doi.org/10.1080/03639040701397381
|
[51]
|
Civiale, C., Licciardi, M., Cavallaro, G., et al. (2009) Polyhy-droxyethylaspartamide-Based Micelles for Ocular Drug Delivery. International Journal of Pharmaceutics, 378, 177-186. https://doi.org/10.1016/j.ijpharm.2009.05.028
|
[52]
|
Balguri, S.P., Adelli, G.R. and Majumdar, S. (2016) Topical Ophthalmic Lipid Nanoparticle Formulations (SLN, NLC) of Indomethacin for Delivery to the Posterior Segment Ocular Tissues. European Journal of Pharmaceutics and Biopharmaceutics, 109, 224-235. https://doi.org/10.1016/j.ejpb.2016.10.015
|
[53]
|
Punyamurthula, N.S., Adelli, G.R., Gul, W., et al. (2017) Ocular Disposition of ∆8-Tetrahydrocannabinol from Various Topical Ophthalmic Formulations. AAPS PharmSciTech, 18, 1936-1945.
https://doi.org/10.1208/s12249-016-0672-2
|